GMAT Question of the Day: Daily via email | Daily via Instagram New to GMAT Club? Watch this Video

 It is currently 24 Feb 2020, 00:39

### GMAT Club Daily Prep

#### Thank you for using the timer - this advanced tool can estimate your performance and suggest more practice questions. We have subscribed you to Daily Prep Questions via email.

Customized
for You

we will pick new questions that match your level based on your Timer History

Track

every week, we’ll send you an estimated GMAT score based on your performance

Practice
Pays

we will pick new questions that match your level based on your Timer History

# A regimen of intrauterine AZT (zidovudine) as a means of reducing the

Author Message
TAGS:

### Hide Tags

Manager
Joined: 13 Oct 2016
Posts: 240
GMAT 1: 600 Q44 V28
A regimen of intrauterine AZT (zidovudine) as a means of reducing the  [#permalink]

### Show Tags

Updated on: 02 Sep 2019, 02:45
5
4
Question 1
00:00

based on 319 sessions

53% (03:11) correct 47% (03:13) wrong

### HideShow timer Statistics

Question 2
00:00

based on 329 sessions

45% (01:27) correct 55% (01:34) wrong

### HideShow timer Statistics

Question 3
00:00

based on 311 sessions

31% (01:31) correct 69% (01:27) wrong

### HideShow timer Statistics

Question 4
00:00

based on 305 sessions

84% (00:35) correct 16% (00:57) wrong

### HideShow timer Statistics

Question 5
00:00

based on 301 sessions

47% (00:53) correct 53% (00:55) wrong

### HideShow timer Statistics

Question 6
00:00

based on 261 sessions

84% (00:21) correct 16% (00:31) wrong

### HideShow timer Statistics

A regimen of intrauterine AZT (zidovudine) as a means of reducing the chances of HIV transmission from mother to child was first described in a study known as Protocol 076, the results of which were published in the New England Journal of Medicine in November 1994. The trial found that administration of AZT to HIV-positive women during pregnancy and delivery, and to their babies after birth, reduced the transmission of HIV to the infants by two thirds, compared with a placebo. The study was acclaimed as one of the first successful instances of a prophylaxis preventing HIV transmission—particularly “vertical” transmission, or transmission from mothers to infants. The study, prematurely ended so that all the subjects on placebos could be switched to AZT, led to the recommendation that all pregnant women with HIV take AZT.

The validity of the study’s results, however, is debatable. Since Protocol 076 examined only women who had fairly high numbers of T-cells—the white blood cells that coordinate immune response—and who had previously taken AZT for less than six months, the same regimen might not succeed for other pregnant women with HIV. Moreover, the study administered large doses of AZT without examining whether lower doses, more economically feasible for uninsured or under insured women, might be effective. Further, the trial design did not account for important variables: in particular, whether the subjects’ viral load—the amount of HIV in their bodies—might have contributed to the difference in transmission rates. Since the exact mechanism and timing of vertical transmission of the HIV virus are unknown, it cannot be ruled out that viral load influences rates of vertical transmission.

Also, the study did not consider the long term impact of AZT, which is toxic, on the babies themselves. There have been few studies of AZT’s effect on HIV-positive infants and none on its effects on uninfected babies. Since the majority of the babies born to HIV-positive women are HIV-negative, and since HIV may mutate into drug-resistant strains following a break in medication, the value of a short term “zap” with AZT becomes suspect.

Q1. The author questions the results of Protocol 076 for which of the following reasons?

A. The number of T-cells was not considered in choosing subjects for the study.
B. The trial was discontinued, and the control group of women on placebo was shifted to AZT.
C. Seventy-five percent of babies born to women in the placebo group were free of infection with HIV.
D. Different transmission rates could have been influenced by different amounts of HIV in the women’s bodies.
E. The exact mechanism and timing of HIV transmission are unknown.

Q2. The author of this passage would be LEAST likely to challenge the benefits of intrauterine AZT for which of the following HIV-positive women and/or their future children?

A. A woman who has used the regimen successfully in a previous pregnancy
B. A woman whose T-cell count is dangerously low and who plans to continue taking AZT after her baby is born
C. A woman who is matched with the study’s subjects in terms of ethnicity and socioeconomic status
D. A woman who has lost a previous infant to HIV and who wants to be sure that her next child is healthy
E. A woman whose T-cell count is not low and who has not taken AZT before

Q3. The passage implies that the “viral loads” of the subjects in the study are significant because

A. all the subjects had relatively high viral loads, so the study’s results may not apply to other groups of women.
C. viral load must be measured if researchers are to understand the exact mechanism and timing of transmission of HIV.
D. the viral loads of women in the placebo group may have been different from those of women in the AZT group.
E. viral load may be a critical factor in determining transmission, but the researchers wrongly assumed that it was the only factor.

Q4. The primary purpose of the passage is to

A. document recent problems with HIV and AIDS treatment.
B. expose medical errors caused by the careless methodology in an important clinical trial.
C. raise doubts about a course of treatment based on a groundbreaking study.
D. describe the process of vertical transmission of HIV and suggest preventive therapy.
E. evaluate treatment possibilities for pregnant women with HIV.

Q5. The author of the passage would be most likely to agree with which of the following statements?

A. Medications harmful to one group of patients are probably not harmful to another.
B. Recommendations based on a conditional experiment must be qualified.
C. The study should not have been prematurely ended.
D. Clinical trials that may harm patients are unethical.
E. No HIV-positive woman should take AZT during pregnancy.

Q6. The primary function of the second paragraph is to

A. refute issues.
B. evaluate solutions.
C. describe results.
D. support action.
E. identify problems.

Originally posted by Kritesh on 02 Jul 2017, 09:04.
Last edited by SajjadAhmad on 02 Sep 2019, 02:45, edited 1 time in total.
Updated - Complete topic (369).
Current Student
Joined: 01 Feb 2018
Posts: 96
Location: India
GMAT 1: 700 Q47 V38
WE: Consulting (Consulting)
Re: A regimen of intrauterine AZT (zidovudine) as a means of reducing the  [#permalink]

### Show Tags

25 Sep 2018, 04:58
5
5 mins, including time to read the passage, 5/6 correct
1.
Quote:
Q1. The author questions the results of Protocol 076 for which of the following reasons?

A. The number of T-cells was not considered in choosing subjects for the study.
B. The trial was discontinued, and the control group of women on placebo was shifted to AZT.
C. Seventy-five percent of babies born to women in the placebo group were free of infection with HIV.
D. Different transmission rates could have been influenced by different amounts of HIV in the women’s bodies.
E. The exact mechanism and timing of HIV transmission are unknown.

Refer to the following lines in the passage :
Quote:
Further, the trial design did not account for important variables: in particular, whether the subjects’ viral load—the amount of HIV in their bodies—might have contributed to the difference in transmission rates. Since the exact mechanism and timing of vertical transmission of the HIV virus are unknown, it cannot be ruled out that viral load influences rates of vertical transmission.

Based on this, option D makes the most sense and is the right answer.

2.
Quote:
Q2. The author of this passage would be LEAST likely to challenge the benefits of intrauterine AZT for which of the following HIV-positive women and/or their future children?

A. A woman who has used the regimen successfully in a previous pregnancy
B. A woman whose T-cell count is dangerously low and who plans to continue taking AZT after her baby is born
C. A woman who is matched with the study’s subjects in terms of ethnicity and socioeconomic status
D. A woman who has lost a previous infant to HIV and who wants to be sure that her next child is healthy
E. A woman whose T-cell count is not low and who has not taken AZT before

I got this one wrong, I was confused between options B and E and incorrectly chose B. But on re-reading the passage I noticed the following lines

Quote:
Since the majority of the babies born to HIV-positive women are HIV-negative, and since HIV may mutate into drug-resistant strains following a break in medication, the value of a short term “zap” with AZT becomes suspect.

So, from this we can understand why E is better. For women who have not taken AZT, the medication will not be resistant and hence will work. I am not sure if my reasoning is correct, workout please clarify.

3.
Quote:
Q3. The passage implies that the “viral loads” of the subjects in the study are significant because

A. all the subjects had relatively high viral loads, so the study’s results may not apply to other groups of women.
C. viral load must be measured if researchers are to understand the exact mechanism and timing of transmission of HIV.
D. the viral loads of women in the placebo group may have been different from those of women in the AZT group.
E. viral load may be a critical factor in determining transmission, but the researchers wrongly assumed that it was the only factor.

Again referring to the following lines from the passage:
Quote:
Further, the trial design did not account for important variables: in particular, whether the subjects’ viral load—the amount of HIV in their bodies—might have contributed to the difference in transmission rates. Since the exact mechanism and timing of vertical transmission of the HIV virus are unknown, it cannot be ruled out that viral load influences rates of vertical transmission.

The passage mentions that the viral loads were significant because they cast a doubt on the validity of the study's results. This further can imply that the viral load of the group of women in the two groups may be different and hence they are significant.

4.
Quote:
Q4. The primary purpose of the passage is to

A. document recent problems with HIV and AIDS treatment.
B. expose medical errors caused by the careless methodology in an important clinical trial.
C. raise doubts about a course of treatment based on a groundbreaking study.
D. describe the process of vertical transmission of HIV and suggest preventive therapy.
E. evaluate treatment possibilities for pregnant women with HIV.

The primary purpose of the passage is to raise doubts on the validity of a particular treatment. This is best captured in answer option C.

5.
Quote:
Q5. The author of the passage would be most likely to agree with which of the following statements?

A. Medications harmful to one group of patients are probably not harmful to another.
B. Recommendations based on a conditional experiment must be qualified.
C. The study should not have been prematurely ended.
D. Clinical trials that may harm patients are unethical.
E. No HIV-positive woman should take AZT during pregnancy.

We can solve this by POE.
A. This is too generic and this has not been mentioned in the passage. We can eliminate A.
B. Yes, this makes sense. We can infer from the passage that results from an experiment need to be qualified. Correct.
C. The passage states that the study was prematurely ended but nowhere is the judgement made whether the study should not have ended prematurely or not. Eliminate C.
D. Not mentioned in the passage, out of scope. Eliminate.
E. Too extreme, not mentioned that no HIV-positive woman should take AZT during pregnancy.

6.
Quote:
Q6. The primary function of the second paragraph is to

A. refute issues.
B. evaluate solutions.
C. describe results.
D. support action.
E. identify problems.

The second paragraph gives us the reasons why the result of the study is debatable. Refer to lines :
Quote:
The validity of the study’s results, however, is debatable.

Considering this, answer option E is correct as we do identify the problems.

If someone could clarify my reasoning for Q2, it would be great!
Thanks,
##### General Discussion
Senior Manager
Joined: 03 Apr 2015
Posts: 251
GMAT 1: 650 Q49 V31
GPA: 3.59
Re: A regimen of intrauterine AZT (zidovudine) as a means of reducing the  [#permalink]

### Show Tags

Updated on: 25 Sep 2018, 06:17
3
Q1. The author questions the results of Protocol 076 for which of the following reasons?

A. The number of T-cells was not considered in choosing subjects for the study.
B. The trial was discontinued, and the control group of women on placebo was shifted to AZT.
C. Seventy-five percent of babies born to women in the placebo group were free of infection with HIV.
D. Different transmission rates could have been influenced by different amounts of HIV in the women’s bodies.
E. The exact mechanism and timing of HIV transmission are unknown.
the main doubt is between D and E but reading the passage we see the it was failure to consider the presence of the factor :transmission rates and not the transmission mechanism that led to question the study
so D

Q2. The author of this passage would be LEAST likely to challenge the benefits of intrauterine AZT for which of the following HIV-positive women and/or their future children?

the author mentions in start of second para : high T cells and less than 6 months duration of AZT

A. A woman who has used the regimen successfully in a previous pregnancy--opposite
B. A woman whose T-cell count is dangerously low and who plans to continue taking AZT after her baby is born---opposite
C. A woman who is matched with the study’s subjects in terms of ethnicity and socioeconomic status--- no correlation
D. A woman who has lost a previous infant to HIV and who wants to be sure that her next child is healthy--- no mention about this
E. A woman whose T-cell count is not low and who has not taken AZT before

Q3. The passage implies that the “viral loads” of the subjects in the study are significant because

A. all the subjects had relatively high viral loads, so the study’s results may not apply to other groups of women.
C. viral load must be measured if researchers are to understand the exact mechanism and timing of transmission of HIV.
D. the viral loads of women in the placebo group may have been different from those of women in the AZT group.
E. viral load may be a critical factor in determining transmission, but the researchers wrongly assumed that it was the only factor.

C and D close ; but C says the mechanism is important where as the author criticizes the failure to consider the rate of the transfer mechanism so D is correct (also gmat tip usage of must in C makes it bad choice)

Q4. The primary purpose of the passage is to

A. document recent problems with HIV and AIDS treatment.
B. expose medical errors caused by the careless methodology in an important clinical trial.
C. raise doubts about a course of treatment based on a groundbreaking study.
D. describe the process of vertical transmission of HIV and suggest preventive therapy.
E. evaluate treatment possibilities for pregnant women with HIV.

Q5. The author of the passage would be most likely to agree with which of the following statements?

A. Medications harmful to one group of patients are probably not harmful to another.
B. Recommendations based on a conditional experiment must be qualified.
C. The study should not have been prematurely ended.
D. Clinical trials that may harm patients are unethical.
E. No HIV-positive woman should take AZT during pregnancy.
slight dilemma between B and C but C wraps the truth ,author not concerned about the duration of study but the study as a whole: so B best

Q6. The primary function of the second paragraph is to

A. refute issues.
B. evaluate solutions.
C. describe results.
D. support action.
E. identify problems.

Originally posted by StrugglingGmat2910 on 25 Sep 2018, 05:53.
Last edited by StrugglingGmat2910 on 25 Sep 2018, 06:17, edited 1 time in total.
Senior Manager
Joined: 03 Apr 2015
Posts: 251
GMAT 1: 650 Q49 V31
GPA: 3.59
Re: A regimen of intrauterine AZT (zidovudine) as a means of reducing the  [#permalink]

### Show Tags

25 Sep 2018, 05:53
1
Sreyoshi007 wrote:
5 mins, including time to read the passage, 5/6 correct
1.
Quote:
Q1. The author questions the results of Protocol 076 for which of the following reasons?

A. The number of T-cells was not considered in choosing subjects for the study.
B. The trial was discontinued, and the control group of women on placebo was shifted to AZT.
C. Seventy-five percent of babies born to women in the placebo group were free of infection with HIV.
D. Different transmission rates could have been influenced by different amounts of HIV in the women’s bodies.
E. The exact mechanism and timing of HIV transmission are unknown.

Refer to the following lines in the passage :
Quote:
Further, the trial design did not account for important variables: in particular, whether the subjects’ viral load—the amount of HIV in their bodies—might have contributed to the difference in transmission rates. Since the exact mechanism and timing of vertical transmission of the HIV virus are unknown, it cannot be ruled out that viral load influences rates of vertical transmission.

Based on this, option D makes the most sense and is the right answer.

2.
Quote:
Q2. The author of this passage would be LEAST likely to challenge the benefits of intrauterine AZT for which of the following HIV-positive women and/or their future children?

A. A woman who has used the regimen successfully in a previous pregnancy
B. A woman whose T-cell count is dangerously low and who plans to continue taking AZT after her baby is born
C. A woman who is matched with the study’s subjects in terms of ethnicity and socioeconomic status
D. A woman who has lost a previous infant to HIV and who wants to be sure that her next child is healthy
E. A woman whose T-cell count is not low and who has not taken AZT before

I got this one wrong, I was confused between options B and E and incorrectly chose B. But on re-reading the passage I noticed the following lines

Quote:
Since the majority of the babies born to HIV-positive women are HIV-negative, and since HIV may mutate into drug-resistant strains following a break in medication, the value of a short term “zap” with AZT becomes suspect.

So, from this we can understand why E is better. For women who have not taken AZT, the medication will not be resistant and hence will work. I am not sure if my reasoning is correct, workout please clarify.

3.
Quote:
Q3. The passage implies that the “viral loads” of the subjects in the study are significant because

A. all the subjects had relatively high viral loads, so the study’s results may not apply to other groups of women.
C. viral load must be measured if researchers are to understand the exact mechanism and timing of transmission of HIV.
D. the viral loads of women in the placebo group may have been different from those of women in the AZT group.
E. viral load may be a critical factor in determining transmission, but the researchers wrongly assumed that it was the only factor.

Again referring to the following lines from the passage:
Quote:
Further, the trial design did not account for important variables: in particular, whether the subjects’ viral load—the amount of HIV in their bodies—might have contributed to the difference in transmission rates. Since the exact mechanism and timing of vertical transmission of the HIV virus are unknown, it cannot be ruled out that viral load influences rates of vertical transmission.

The passage mentions that the viral loads were significant because they cast a doubt on the validity of the study's results. This further can imply that the viral load of the group of women in the two groups may be different and hence they are significant.

4.
Quote:
Q4. The primary purpose of the passage is to

A. document recent problems with HIV and AIDS treatment.
B. expose medical errors caused by the careless methodology in an important clinical trial.
C. raise doubts about a course of treatment based on a groundbreaking study.
D. describe the process of vertical transmission of HIV and suggest preventive therapy.
E. evaluate treatment possibilities for pregnant women with HIV.

The primary purpose of the passage is to raise doubts on the validity of a particular treatment. This is best captured in answer option C.

5.
Quote:
Q5. The author of the passage would be most likely to agree with which of the following statements?

A. Medications harmful to one group of patients are probably not harmful to another.
B. Recommendations based on a conditional experiment must be qualified.
C. The study should not have been prematurely ended.
D. Clinical trials that may harm patients are unethical.
E. No HIV-positive woman should take AZT during pregnancy.

We can solve this by POE.
A. This is too generic and this has not been mentioned in the passage. We can eliminate A.
B. Yes, this makes sense. We can infer from the passage that results from an experiment need to be qualified. Correct.
C. The passage states that the study was prematurely ended but nowhere is the judgement made whether the study should not have ended prematurely or not. Eliminate C.
D. Not mentioned in the passage, out of scope. Eliminate.
E. Too extreme, not mentioned that no HIV-positive woman should take AZT during pregnancy.

6.
Quote:
Q6. The primary function of the second paragraph is to

A. refute issues.
B. evaluate solutions.
C. describe results.
D. support action.
E. identify problems.

The second paragraph gives us the reasons why the result of the study is debatable. Refer to lines :
Quote:
The validity of the study’s results, however, is debatable.

Considering this, answer option E is correct as we do identify the problems.

If someone could clarify my reasoning for Q2, it would be great!
Thanks,

Q2. The author of this passage would be LEAST likely to challenge the benefits of intrauterine AZT for which of the following HIV-positive women and/or their future children?

the author mentions in start of second para : high T cells and less than 6 months duration of AZT

A. A woman who has used the regimen successfully in a previous pregnancy--opposite
B. A woman whose T-cell count is dangerously low and who plans to continue taking AZT after her baby is born---opposite
C. A woman who is matched with the study’s subjects in terms of ethnicity and socioeconomic status--- no correlation
D. A woman who has lost a previous infant to HIV and who wants to be sure that her next child is healthy--- no mention about this
E. A woman whose T-cell count is not low and who has not taken AZT before
Intern
Joined: 22 Jan 2018
Posts: 8
Re: A regimen of intrauterine AZT (zidovudine) as a means of reducing the  [#permalink]

### Show Tags

25 Sep 2018, 06:04
Why the answer for Q1 is D not E as option E is clerarly stated in para last lines.

Posted from my mobile device
Senior Manager
Joined: 03 Apr 2015
Posts: 251
GMAT 1: 650 Q49 V31
GPA: 3.59
Re: A regimen of intrauterine AZT (zidovudine) as a means of reducing the  [#permalink]

### Show Tags

25 Sep 2018, 06:19
naina0001 wrote:
Why the answer for Q1 is D not E as option E is clerarly stated in para last lines.

Posted from my mobile device

As far as I understood it was not option E although being stated is the reason for the study being disqualified but lack of considering the rates in the study was the reason so D is best
Manager
Joined: 23 Dec 2011
Posts: 53
Re: A regimen of intrauterine AZT (zidovudine) as a means of reducing the  [#permalink]

### Show Tags

25 Sep 2018, 07:20
Q2. The author of this passage would be LEAST likely to challenge the benefits of intrauterine AZT for which of the following HIV-positive women and/or their future children?

A. A woman who has used the regimen successfully in a previous pregnancy
B. A woman whose T-cell count is dangerously low and who plans to continue taking AZT after her baby is born
C. A woman who is matched with the study’s subjects in terms of ethnicity and socioeconomic status
D. A woman who has lost a previous infant to HIV and who wants to be sure that her next child is healthy
E. A woman whose T-cell count is not low and who has not taken AZT before

Can someone please explain why E is correct, based on the following statements from the passage I can understand that “A woman whose T-cell count is not low” is correct -
Since Protocol 076 examined only women who had fairly high numbers of T-cells—the white blood cells that coordinate immune response—and who had previously taken AZT for less than six months
But the second part of the answer choice says that “who has not taken AZT before”, and the from the above statements from the passage it says that “who had previously taken AZT for less than six months”
Retired Moderator
Joined: 23 Sep 2015
Posts: 1711
Re: A regimen of intrauterine AZT (zidovudine) as a means of reducing the  [#permalink]

### Show Tags

25 Sep 2018, 08:15
2
P1 - AZT its usefulness
P2 - contrast from P1;
P3 - more bad roles of AZT

Main point - AZT is good in certain case, but bad in other many cases.

Q1. The author questions the results of Protocol 076 for which of the following reasons?
this is done in p2 and p3

D. Different transmission rates could have been influenced by different amounts of HIV in the women’s bodies. - yes ; in particular, whether the subjects’ viral load—the amount of HIV in their bodies—might have contributed to the difference in transmission rates.
------------------------------------------------
Q2. The author of this passage would be LEAST likely to challenge the benefits of intrauterine AZT for which of the following HIV-positive women and/or their future children?
answer should be in P1/p2. ---- women who had fairly high numbers of T-cells—the white blood cells that coordinate immune response—and who had previously taken AZT for less than six months, the same regimen might not succeed for other pregnant women with HIV.

A. A woman who has used the regimen successfully in a previous pregnancy - no
B. A woman whose T-cell count is dangerously low and who plans to continue taking AZT after her baby is born - no
C. A woman who is matched with the study’s subjects in terms of ethnicity and socioeconomic status - no
D. A woman who has lost a previous infant to HIV and who wants to be sure that her next child is healthy - no
E. A woman whose T-cell count is not low and who has not taken AZT before - yes

-----------------------------------------------

Q3. The passage implies that the viral loads” of the subjects in the study are significant because
whether the subjects’ viral load—the amount of HIV in their bodies—might have contributed to the difference in transmission rates.

The trial found that administration of AZT to HIV-positive women during pregnancy and delivery, and to their babies after birth, reduced the transmission of HIV to the infants by two thirds, compared with a placebo.

D. the viral loads of women in the placebo group may have been different from those of women in the AZT group. - y

-----------------------------------------------

Q4. The primary purpose of the passage is to

A. document recent problems with HIV and AIDS treatment. - no
B. expose medical errors caused by the careless methodology in an important clinical trial. - yes but aim of author is to reject AZt.
C. raise doubts about a course of treatment based on a groundbreaking study. - more close to main point.
D. describe the process of vertical transmission of HIV and suggest preventive therapy. - no
E. evaluate treatment possibilities for pregnant women with HIV. - no

----------------------------------------------
Q5. The author of the passage would be most likely to agree with which of the following statements?

A. Medications harmful to one group of patients are probably not harmful to another. - too braod
B. Recommendations based on a conditional experiment must be qualified. - closest
C. The study should not have been prematurely ended. - no; not mentioned.
D. Clinical trials that may harm patients are unethical. - no; not mentioned.
E. No HIV-positive woman should take AZT during pregnancy. - no; too braod

----------------------------------------------
Q6. The primary function of the second paragraph is to
Contrast the p1

E. identify problems. - has to be this.
_________________
Simple strategy:
“Once you’ve eliminated the impossible, whatever remains, however improbable, must be the truth.”

GMAT Ninja YouTube! Series 1| GMAT Ninja YouTube! Series 2 | How to Improve GMAT Quant from Q49 to a Perfect Q51 | Time management

My Notes:
Reading comprehension | Critical Reasoning | Absolute Phrases | Subjunctive Mood
Manager
Joined: 23 Aug 2016
Posts: 101
Location: India
Concentration: Finance, Strategy
GMAT 1: 660 Q49 V31
GPA: 2.84
WE: Other (Energy and Utilities)
Re: A regimen of intrauterine AZT (zidovudine) as a means of reducing the  [#permalink]

### Show Tags

26 Sep 2018, 01:49
1
Kritesh wrote:
A regimen of intrauterine AZT (zidovudine) as a means of reducing the chances of HIV transmission from mother to child was first described in a study known as Protocol 076, the results of which were published in the New England Journal of Medicine in November 1994. The trial found that administration of AZT to HIV-positive women during pregnancy and delivery, and to their babies after birth, reduced the transmission of HIV to the infants by two thirds, compared with a placebo. The study was acclaimed as one of the first successful instances of a prophylaxis preventing HIV transmission—particularly “vertical” transmission, or transmission from mothers to infants. The study, prematurely ended so that all the subjects on placebos could be switched to AZT, led to the recommendation that all pregnant women with HIV take AZT.

The validity of the study’s results, however, is debatable. Since Protocol 076 examined only women who had fairly high numbers of T-cells—the white blood cells that coordinate immune response—and who had previously taken AZT for less than six months, the same regimen might not succeed for other pregnant women with HIV. Moreover, the study administered large doses of AZT without examining whether lower doses, more economically feasible for uninsured or under insured women, might be effective. Further, the trial design did not account for important variables: in particular, whether the subjects’ viral load—the amount of HIV in their bodies—might have contributed to the difference in transmission rates. Since the exact mechanism and timing of vertical transmission of the HIV virus are unknown, it cannot be ruled out that viral load influences rates of vertical transmission.

Also, the study did not consider the long term impact of AZT, which is toxic, on the babies themselves. There have been few studies of AZT’s effect on HIV-positive infants and none on its effects on uninfected babies. Since the majority of the babies born to HIV-positive women are HIV-negative, and since HIV may mutate into drug-resistant strains following a break in medication, the value of a short term “zap” with AZT becomes suspect.
Q1. The author questions the results of Protocol 076 for which of the following reasons?

A. The number of T-cells was not considered in choosing subjects for the study.
B. The trial was discontinued, and the control group of women on placebo was shifted to AZT.
C. Seventy-five percent of babies born to women in the placebo group were free of infection with HIV.
D. Different transmission rates could have been influenced by different amounts of HIV in the women’s bodies.
E. The exact mechanism and timing of HIV transmission are unknown.

Q2. The author of this passage would be LEAST likely to challenge the benefits of intrauterine AZT for which of the following HIV-positive women and/or their future children?

A. A woman who has used the regimen successfully in a previous pregnancy
B. A woman whose T-cell count is dangerously low and who plans to continue taking AZT after her baby is born
C. A woman who is matched with the study’s subjects in terms of ethnicity and socioeconomic status
D. A woman who has lost a previous infant to HIV and who wants to be sure that her next child is healthy
E. A woman whose T-cell count is not low and who has not taken AZT before

Q3. The passage implies that the “viral loads” of the subjects in the study are significant because

A. all the subjects had relatively high viral loads, so the study’s results may not apply to other groups of women.
C. viral load must be measured if researchers are to understand the exact mechanism and timing of transmission of HIV.
D. the viral loads of women in the placebo group may have been different from those of women in the AZT group.
E. viral load may be a critical factor in determining transmission, but the researchers wrongly assumed that it was the only factor.

Q4. The primary purpose of the passage is to

A. document recent problems with HIV and AIDS treatment.
B. expose medical errors caused by the careless methodology in an important clinical trial.
C. raise doubts about a course of treatment based on a groundbreaking study.
D. describe the process of vertical transmission of HIV and suggest preventive therapy.
E. evaluate treatment possibilities for pregnant women with HIV.

Q5. The author of the passage would be most likely to agree with which of the following statements?

A. Medications harmful to one group of patients are probably not harmful to another.
B. Recommendations based on a conditional experiment must be qualified.
C. The study should not have been prematurely ended.
D. Clinical trials that may harm patients are unethical.
E. No HIV-positive woman should take AZT during pregnancy.

Q6. The primary function of the second paragraph is to

A. refute issues.
B. evaluate solutions.
C. describe results.
D. support action.
E. identify problems.

Here are my 2 cents-

Q1. The author questions the results of Protocol 076 for which of the following reasons?

A. The number of T-cells was not considered in choosing subjects for the study-Out of scope
B. The trial was discontinued, and the control group of women on placebo was shifted to AZT.-True but not the the reason author questions the study
C. Seventy-five percent of babies born to women in the placebo group were free of infection with HIV.-not seventy five percent but 66.66%(2/3) not (3/4).
D. Different transmission rates could have been influenced by different amounts of HIV in the women’s bodies-Correct"Further, the trial design did not account for important variables: in particular, whether the subjects’ viral load—the amount of HIV in their bodies—might have contributed to the difference in transmission rates."
E. The exact mechanism and timing of HIV transmission are unknown.

Q2. The author of this passage would be LEAST likely to challenge the benefits of intrauterine AZT for which of the following HIV-positive women and/or their future children?

A. A woman who has used the regimen successfully in a previous pregnancy-No author would discourage such a use!
B. A woman whose T-cell count is dangerously low and who plans to continue taking AZT after her baby is born-No author would discourage such a use!
C. A woman who is matched with the study’s subjects in terms of ethnicity and socioeconomic status-Out of scope
D. A woman who has lost a previous infant to HIV and who wants to be sure that her next child is healthy-No author would discourage such a use!
E. A woman whose T-cell count is not low and who has not taken AZT before-Correct, refer"Since Protocol 076 examined only women who had fairly high numbers of T-cells—the white blood cells that coordinate immune response—and who had previously taken AZT for less than six months, the same regimen might not succeed for other pregnant women with HIV."

Q3. The passage implies that the “viral loads” of the subjects in the study are significant because

A. all the subjects had relatively high viral loads, so the study’s results may not apply to other groups of women-Wrong! no where mentioned.
B. the viral loads of babies whose mothers had received the placebo were just as high as those of babies whose mothers had received AZT.-Wrong! no where mentioned.
C. viral load must be measured if researchers are to understand the exact mechanism and timing of transmission of HIV.-True but not the answer
D. the viral loads of women in the placebo group may have been different from those of women in the AZT group.-Correct refer passage.
E. viral load may be a critical factor in determining transmission, but the researchers wrongly assumed that it was the only factor.-Incorrect, "WRONGLY ASSUMED" is no where inferred.

Q4. The primary purpose of the passage is to

A. document recent problems with HIV and AIDS treatment.-Wrong! nothing about AIDS!
B. expose medical errors caused by the careless methodology in an important clinical trial-Wrong! Careless methodology is too strong.
C. raise doubts about a course of treatment based on a groundbreaking study.-Correct, Author details a path breaking process and goes on to infer its limitations and doubts on the validity of study!
D. describe the process of vertical transmission of HIV and suggest preventive therapy.-Partial scope
E. evaluate treatment possibilities for pregnant women with HIV.-Partial scope.

Q5. The author of the passage would be most likely to agree with which of the following statements?

A. Medications harmful to one group of patients are probably not harmful to another.-Nowhere mentioned
B. Recommendations based on a conditional experiment must be qualified.-Correct, Author supports that the trial should be qualified !
C. The study should not have been prematurely ended.-Study did ended prematurely but author supports or refutes is no where mentioned.
D. Clinical trials that may harm patients are unethical.-Nowhere mentioned
E. No HIV-positive woman should take AZT during pregnancy.-Nowhere mentioned

Q6. The primary function of the second paragraph is to

A. refute issues.-Wrong! no issues are refuted.
B. evaluate solutions.-Umm, kinda right! Keep it for now!
C. describe results.-NO results are described rather the basis on which result is reached is described.
D. support action.-No suppor to action.
E. identify problems.-Kinda right! author does talks about problems! Correct !

I will select E over B.

[/box_in][/box_out][/quote]
Manager
Joined: 23 Aug 2016
Posts: 101
Location: India
Concentration: Finance, Strategy
GMAT 1: 660 Q49 V31
GPA: 2.84
WE: Other (Energy and Utilities)
Re: A regimen of intrauterine AZT (zidovudine) as a means of reducing the  [#permalink]

### Show Tags

26 Sep 2018, 02:49
workout wrote:

+1 kudos to the posts containing answer explanations of all questions

Hi workout,

Q6. The primary function of the second paragraph is to

A. refute issues.-Wrong! no issues are refuted.
B. evaluate solutions.-Umm, kinda right! Keep it for now!
C. describe results.-NO results are described rather the basis on which result is reached is described.
D. support action.-No suppor to action.
E. identify problems.-Kinda right! author does talks about problems! Correct !

I was terribly divided between B and E but fortunately selected E but what is the major flaw in B?

Manager
Joined: 03 Dec 2018
Posts: 164
Re: A regimen of intrauterine AZT (zidovudine) as a means of reducing the  [#permalink]

### Show Tags

25 Mar 2019, 06:09
Please Explain Q3. C vs D
Q5) B vs C
Intern
Status: when you say,"I can or I can't", Both times you are right!
Joined: 26 Nov 2018
Posts: 31
Location: India
Re: A regimen of intrauterine AZT (zidovudine) as a means of reducing the  [#permalink]

### Show Tags

28 Mar 2019, 02:02
mallya12 wrote:
Please Explain Q3. C vs D
Q5) B vs C

Q3. C vs D

"Since the exact mechanism and timing of vertical transmission of the HIV virus are unknown, it cannot be ruled out that viral load influences rates of vertical transmission."
It implies Viral load could be the factor.
what if we can find the exact mechanism in which viral load did not play any role; Hence, statement 'C' which says viral load must be studied is wrong.
Option D: says viral load could be the factor: which is exactly passage implies.

Q5) B vs C

research can be prematurely ended therefore scientists ended the research, but research should be qualified to be prematurely ended.

Option B: research should be qualified

Thanks = Kudos
Re: A regimen of intrauterine AZT (zidovudine) as a means of reducing the   [#permalink] 28 Mar 2019, 02:02
Display posts from previous: Sort by